skip to Main Content

Cover image of TAG Policy Brief: Hepatitis C and COVID-19 Global Concerns Cover of November 2020 TAGline: 'The Struggle of a Lifetime' (Continued) Homepage slider image of cover of Tuberculosis Research Funding Trends, 2005-2019
Image montage of TAG Limited Art Editions
Image link to About the COVID-19 Project page
Research in Action Awards 2020 - watch the video now!

Pipeline Reports

The current ones are all online and available for download now.

 

 

 

May 11, 2021
Unique Barriers to COVID-19 Vaccine Access for Black Communities
Webinar / Presentation
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

May 10, 2021
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

May 10, 2021
The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times
Publication
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not…

May 6, 2021
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
Statement / Press
Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

May 6, 2021
Landmark TB Trials Results Published in New England Journal of Medicine
Statement / Press
Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.

Back To Top